Family History
441 articles
Which Is the Best Screening Method for Pancreatic Cancer?
Dr. Aimee Lucas outlines the pros and cons of various screening methods that can be used for pancreatic cancer, and who should be using them.
Earlier Detection of Pancreatic Cancer: A Marathon, Not A Sprint
Dino Verrelli of Project Purple joins with Dr. Diane Simeone on the PRECEDE Consortium to develop earlier detection and new pancreatic cancer treatments.
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
Focusing on a Drug that Treats Specific Tumor Mutations
A clinical trial tests a signal-inhibiting drug for lung cancers with specific genetic mutations on gastrointestinal cancers with the same tumor mutations.
New Drug for BRCA Carriers with Advanced Cancer
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Using Molecular Tumor Profiling to Determine the Best Pancreatic Cancer Treatment
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.